Global Psoriasis Biosimilar Market Growth 2026-2032
The global Psoriasis Biosimilar market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
A psoriasis biosimilar refers to a biologic drug that is highly similar to an existing FDA-approved biologic treatment (the reference product) used for treating psoriasis, a chronic autoimmune condition that causes rapid skin cell turnover, leading to scales and inflamed patches of skin. Biosimilars are developed after the original biologic's patent expires and are designed to be equally effective, safe, and of the same high quality as the original.
United States market for Psoriasis Biosimilar is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Psoriasis Biosimilar is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Psoriasis Biosimilar is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Psoriasis Biosimilar players cover Merck KGaA, Gyros Protein Technologies AB, Pfizer Inc., Novartis International AG, Amgen Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Psoriasis Biosimilar Industry Forecast” looks at past sales and reviews total world Psoriasis Biosimilar sales in 2025, providing a comprehensive analysis by region and market sector of projected Psoriasis Biosimilar sales for 2026 through 2032. With Psoriasis Biosimilar sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Psoriasis Biosimilar industry.
This Insight Report provides a comprehensive analysis of the global Psoriasis Biosimilar landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Psoriasis Biosimilar portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Psoriasis Biosimilar market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Psoriasis Biosimilar and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Psoriasis Biosimilar.
This report presents a comprehensive overview, market shares, and growth opportunities of Psoriasis Biosimilar market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
A psoriasis biosimilar refers to a biologic drug that is highly similar to an existing FDA-approved biologic treatment (the reference product) used for treating psoriasis, a chronic autoimmune condition that causes rapid skin cell turnover, leading to scales and inflamed patches of skin. Biosimilars are developed after the original biologic's patent expires and are designed to be equally effective, safe, and of the same high quality as the original.
United States market for Psoriasis Biosimilar is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Psoriasis Biosimilar is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Psoriasis Biosimilar is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Psoriasis Biosimilar players cover Merck KGaA, Gyros Protein Technologies AB, Pfizer Inc., Novartis International AG, Amgen Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Psoriasis Biosimilar Industry Forecast” looks at past sales and reviews total world Psoriasis Biosimilar sales in 2025, providing a comprehensive analysis by region and market sector of projected Psoriasis Biosimilar sales for 2026 through 2032. With Psoriasis Biosimilar sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Psoriasis Biosimilar industry.
This Insight Report provides a comprehensive analysis of the global Psoriasis Biosimilar landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Psoriasis Biosimilar portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Psoriasis Biosimilar market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Psoriasis Biosimilar and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Psoriasis Biosimilar.
This report presents a comprehensive overview, market shares, and growth opportunities of Psoriasis Biosimilar market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
- Other Biosimilars
- Plaque Psoriasis
- Psoriatic Arthritis
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Merck KGaA
- Gyros Protein Technologies AB
- Pfizer Inc.
- Novartis International AG
- Amgen Inc
- Samsung Bioepis Co., Ltd.
- Coherus BioSciences
- Hoffmann-La Roche Ltd
- Celltrion
- Samsung Bioepis
- Sandoz
- Fresenius Kabi
- Viatris
- Reddy's Laboratories
- GenScript
- What is the 10-year outlook for the global Psoriasis Biosimilar market?
- What factors are driving Psoriasis Biosimilar market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Psoriasis Biosimilar market opportunities vary by end market size?
- How does Psoriasis Biosimilar break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Psoriasis Biosimilar Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Psoriasis Biosimilar by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Psoriasis Biosimilar by Country/Region, 2021, 2025 & 2032
2.2 Psoriasis Biosimilar Segment by Type
2.2.1 TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
2.2.2 Other Biosimilars
2.2.3 Psoriasis Biosimilar Sales by Type
2.2.3.1 Global Psoriasis Biosimilar Sales Market Share by Type (2021-2026)
2.2.3.2 Global Psoriasis Biosimilar Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Psoriasis Biosimilar Sale Price by Type (2021-2026)
2.3 Psoriasis Biosimilar Segment by Application
2.3.1 Plaque Psoriasis
2.3.2 Psoriatic Arthritis
2.3.3 Other
2.3.4 Psoriasis Biosimilar Sales by Application
2.3.4.1 Global Psoriasis Biosimilar Sale Market Share by Application (2021-2026)
2.3.4.2 Global Psoriasis Biosimilar Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Psoriasis Biosimilar Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Psoriasis Biosimilar Breakdown Data by Company
3.1.1 Global Psoriasis Biosimilar Annual Sales by Company (2021-2026)
3.1.2 Global Psoriasis Biosimilar Sales Market Share by Company (2021-2026)
3.2 Global Psoriasis Biosimilar Annual Revenue by Company (2021-2026)
3.2.1 Global Psoriasis Biosimilar Revenue by Company (2021-2026)
3.2.2 Global Psoriasis Biosimilar Revenue Market Share by Company (2021-2026)
3.3 Global Psoriasis Biosimilar Sale Price by Company
3.4 Key Manufacturers Psoriasis Biosimilar Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Psoriasis Biosimilar Product Location Distribution
3.4.2 Players Psoriasis Biosimilar Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PSORIASIS BIOSIMILAR BY GEOGRAPHIC REGION
4.1 World Historic Psoriasis Biosimilar Market Size by Geographic Region (2021-2026)
4.1.1 Global Psoriasis Biosimilar Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Psoriasis Biosimilar Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Psoriasis Biosimilar Market Size by Country/Region (2021-2026)
4.2.1 Global Psoriasis Biosimilar Annual Sales by Country/Region (2021-2026)
4.2.2 Global Psoriasis Biosimilar Annual Revenue by Country/Region (2021-2026)
4.3 Americas Psoriasis Biosimilar Sales Growth
4.4 APAC Psoriasis Biosimilar Sales Growth
4.5 Europe Psoriasis Biosimilar Sales Growth
4.6 Middle East & Africa Psoriasis Biosimilar Sales Growth
5 AMERICAS
5.1 Americas Psoriasis Biosimilar Sales by Country
5.1.1 Americas Psoriasis Biosimilar Sales by Country (2021-2026)
5.1.2 Americas Psoriasis Biosimilar Revenue by Country (2021-2026)
5.2 Americas Psoriasis Biosimilar Sales by Type (2021-2026)
5.3 Americas Psoriasis Biosimilar Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Psoriasis Biosimilar Sales by Region
6.1.1 APAC Psoriasis Biosimilar Sales by Region (2021-2026)
6.1.2 APAC Psoriasis Biosimilar Revenue by Region (2021-2026)
6.2 APAC Psoriasis Biosimilar Sales by Type (2021-2026)
6.3 APAC Psoriasis Biosimilar Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Psoriasis Biosimilar by Country
7.1.1 Europe Psoriasis Biosimilar Sales by Country (2021-2026)
7.1.2 Europe Psoriasis Biosimilar Revenue by Country (2021-2026)
7.2 Europe Psoriasis Biosimilar Sales by Type (2021-2026)
7.3 Europe Psoriasis Biosimilar Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Psoriasis Biosimilar by Country
8.1.1 Middle East & Africa Psoriasis Biosimilar Sales by Country (2021-2026)
8.1.2 Middle East & Africa Psoriasis Biosimilar Revenue by Country (2021-2026)
8.2 Middle East & Africa Psoriasis Biosimilar Sales by Type (2021-2026)
8.3 Middle East & Africa Psoriasis Biosimilar Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Psoriasis Biosimilar
10.3 Manufacturing Process Analysis of Psoriasis Biosimilar
10.4 Industry Chain Structure of Psoriasis Biosimilar
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Psoriasis Biosimilar Distributors
11.3 Psoriasis Biosimilar Customer
12 WORLD FORECAST REVIEW FOR PSORIASIS BIOSIMILAR BY GEOGRAPHIC REGION
12.1 Global Psoriasis Biosimilar Market Size Forecast by Region
12.1.1 Global Psoriasis Biosimilar Forecast by Region (2027-2032)
12.1.2 Global Psoriasis Biosimilar Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Psoriasis Biosimilar Forecast by Type (2027-2032)
12.7 Global Psoriasis Biosimilar Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Merck KGaA
13.1.1 Merck KGaA Company Information
13.1.2 Merck KGaA Psoriasis Biosimilar Product Portfolios and Specifications
13.1.3 Merck KGaA Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Merck KGaA Main Business Overview
13.1.5 Merck KGaA Latest Developments
13.2 Gyros Protein Technologies AB
13.2.1 Gyros Protein Technologies AB Company Information
13.2.2 Gyros Protein Technologies AB Psoriasis Biosimilar Product Portfolios and Specifications
13.2.3 Gyros Protein Technologies AB Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Gyros Protein Technologies AB Main Business Overview
13.2.5 Gyros Protein Technologies AB Latest Developments
13.3 Pfizer Inc.
13.3.1 Pfizer Inc. Company Information
13.3.2 Pfizer Inc. Psoriasis Biosimilar Product Portfolios and Specifications
13.3.3 Pfizer Inc. Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Pfizer Inc. Main Business Overview
13.3.5 Pfizer Inc. Latest Developments
13.4 Novartis International AG
13.4.1 Novartis International AG Company Information
13.4.2 Novartis International AG Psoriasis Biosimilar Product Portfolios and Specifications
13.4.3 Novartis International AG Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Novartis International AG Main Business Overview
13.4.5 Novartis International AG Latest Developments
13.5 Amgen Inc
13.5.1 Amgen Inc Company Information
13.5.2 Amgen Inc Psoriasis Biosimilar Product Portfolios and Specifications
13.5.3 Amgen Inc Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Amgen Inc Main Business Overview
13.5.5 Amgen Inc Latest Developments
13.6 Samsung Bioepis Co., Ltd.
13.6.1 Samsung Bioepis Co., Ltd. Company Information
13.6.2 Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Product Portfolios and Specifications
13.6.3 Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Samsung Bioepis Co., Ltd. Main Business Overview
13.6.5 Samsung Bioepis Co., Ltd. Latest Developments
13.7 Coherus BioSciences
13.7.1 Coherus BioSciences Company Information
13.7.2 Coherus BioSciences Psoriasis Biosimilar Product Portfolios and Specifications
13.7.3 Coherus BioSciences Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Coherus BioSciences Main Business Overview
13.7.5 Coherus BioSciences Latest Developments
13.8 Hoffmann-La Roche Ltd
13.8.1 Hoffmann-La Roche Ltd Company Information
13.8.2 Hoffmann-La Roche Ltd Psoriasis Biosimilar Product Portfolios and Specifications
13.8.3 Hoffmann-La Roche Ltd Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Hoffmann-La Roche Ltd Main Business Overview
13.8.5 Hoffmann-La Roche Ltd Latest Developments
13.9 Celltrion
13.9.1 Celltrion Company Information
13.9.2 Celltrion Psoriasis Biosimilar Product Portfolios and Specifications
13.9.3 Celltrion Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Celltrion Main Business Overview
13.9.5 Celltrion Latest Developments
13.10 Samsung Bioepis
13.10.1 Samsung Bioepis Company Information
13.10.2 Samsung Bioepis Psoriasis Biosimilar Product Portfolios and Specifications
13.10.3 Samsung Bioepis Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Samsung Bioepis Main Business Overview
13.10.5 Samsung Bioepis Latest Developments
13.11 Sandoz
13.11.1 Sandoz Company Information
13.11.2 Sandoz Psoriasis Biosimilar Product Portfolios and Specifications
13.11.3 Sandoz Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Sandoz Main Business Overview
13.11.5 Sandoz Latest Developments
13.12 Fresenius Kabi
13.12.1 Fresenius Kabi Company Information
13.12.2 Fresenius Kabi Psoriasis Biosimilar Product Portfolios and Specifications
13.12.3 Fresenius Kabi Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Fresenius Kabi Main Business Overview
13.12.5 Fresenius Kabi Latest Developments
13.13 Viatris
13.13.1 Viatris Company Information
13.13.2 Viatris Psoriasis Biosimilar Product Portfolios and Specifications
13.13.3 Viatris Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Viatris Main Business Overview
13.13.5 Viatris Latest Developments
13.14 Reddy's Laboratories
13.14.1 Reddy's Laboratories Company Information
13.14.2 Reddy's Laboratories Psoriasis Biosimilar Product Portfolios and Specifications
13.14.3 Reddy's Laboratories Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Reddy's Laboratories Main Business Overview
13.14.5 Reddy's Laboratories Latest Developments
13.15 GenScript
13.15.1 GenScript Company Information
13.15.2 GenScript Psoriasis Biosimilar Product Portfolios and Specifications
13.15.3 GenScript Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 GenScript Main Business Overview
13.15.5 GenScript Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Psoriasis Biosimilar Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Psoriasis Biosimilar by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Psoriasis Biosimilar by Country/Region, 2021, 2025 & 2032
2.2 Psoriasis Biosimilar Segment by Type
2.2.1 TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
2.2.2 Other Biosimilars
2.2.3 Psoriasis Biosimilar Sales by Type
2.2.3.1 Global Psoriasis Biosimilar Sales Market Share by Type (2021-2026)
2.2.3.2 Global Psoriasis Biosimilar Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Psoriasis Biosimilar Sale Price by Type (2021-2026)
2.3 Psoriasis Biosimilar Segment by Application
2.3.1 Plaque Psoriasis
2.3.2 Psoriatic Arthritis
2.3.3 Other
2.3.4 Psoriasis Biosimilar Sales by Application
2.3.4.1 Global Psoriasis Biosimilar Sale Market Share by Application (2021-2026)
2.3.4.2 Global Psoriasis Biosimilar Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Psoriasis Biosimilar Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Psoriasis Biosimilar Breakdown Data by Company
3.1.1 Global Psoriasis Biosimilar Annual Sales by Company (2021-2026)
3.1.2 Global Psoriasis Biosimilar Sales Market Share by Company (2021-2026)
3.2 Global Psoriasis Biosimilar Annual Revenue by Company (2021-2026)
3.2.1 Global Psoriasis Biosimilar Revenue by Company (2021-2026)
3.2.2 Global Psoriasis Biosimilar Revenue Market Share by Company (2021-2026)
3.3 Global Psoriasis Biosimilar Sale Price by Company
3.4 Key Manufacturers Psoriasis Biosimilar Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Psoriasis Biosimilar Product Location Distribution
3.4.2 Players Psoriasis Biosimilar Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PSORIASIS BIOSIMILAR BY GEOGRAPHIC REGION
4.1 World Historic Psoriasis Biosimilar Market Size by Geographic Region (2021-2026)
4.1.1 Global Psoriasis Biosimilar Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Psoriasis Biosimilar Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Psoriasis Biosimilar Market Size by Country/Region (2021-2026)
4.2.1 Global Psoriasis Biosimilar Annual Sales by Country/Region (2021-2026)
4.2.2 Global Psoriasis Biosimilar Annual Revenue by Country/Region (2021-2026)
4.3 Americas Psoriasis Biosimilar Sales Growth
4.4 APAC Psoriasis Biosimilar Sales Growth
4.5 Europe Psoriasis Biosimilar Sales Growth
4.6 Middle East & Africa Psoriasis Biosimilar Sales Growth
5 AMERICAS
5.1 Americas Psoriasis Biosimilar Sales by Country
5.1.1 Americas Psoriasis Biosimilar Sales by Country (2021-2026)
5.1.2 Americas Psoriasis Biosimilar Revenue by Country (2021-2026)
5.2 Americas Psoriasis Biosimilar Sales by Type (2021-2026)
5.3 Americas Psoriasis Biosimilar Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Psoriasis Biosimilar Sales by Region
6.1.1 APAC Psoriasis Biosimilar Sales by Region (2021-2026)
6.1.2 APAC Psoriasis Biosimilar Revenue by Region (2021-2026)
6.2 APAC Psoriasis Biosimilar Sales by Type (2021-2026)
6.3 APAC Psoriasis Biosimilar Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Psoriasis Biosimilar by Country
7.1.1 Europe Psoriasis Biosimilar Sales by Country (2021-2026)
7.1.2 Europe Psoriasis Biosimilar Revenue by Country (2021-2026)
7.2 Europe Psoriasis Biosimilar Sales by Type (2021-2026)
7.3 Europe Psoriasis Biosimilar Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Psoriasis Biosimilar by Country
8.1.1 Middle East & Africa Psoriasis Biosimilar Sales by Country (2021-2026)
8.1.2 Middle East & Africa Psoriasis Biosimilar Revenue by Country (2021-2026)
8.2 Middle East & Africa Psoriasis Biosimilar Sales by Type (2021-2026)
8.3 Middle East & Africa Psoriasis Biosimilar Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Psoriasis Biosimilar
10.3 Manufacturing Process Analysis of Psoriasis Biosimilar
10.4 Industry Chain Structure of Psoriasis Biosimilar
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Psoriasis Biosimilar Distributors
11.3 Psoriasis Biosimilar Customer
12 WORLD FORECAST REVIEW FOR PSORIASIS BIOSIMILAR BY GEOGRAPHIC REGION
12.1 Global Psoriasis Biosimilar Market Size Forecast by Region
12.1.1 Global Psoriasis Biosimilar Forecast by Region (2027-2032)
12.1.2 Global Psoriasis Biosimilar Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Psoriasis Biosimilar Forecast by Type (2027-2032)
12.7 Global Psoriasis Biosimilar Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Merck KGaA
13.1.1 Merck KGaA Company Information
13.1.2 Merck KGaA Psoriasis Biosimilar Product Portfolios and Specifications
13.1.3 Merck KGaA Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Merck KGaA Main Business Overview
13.1.5 Merck KGaA Latest Developments
13.2 Gyros Protein Technologies AB
13.2.1 Gyros Protein Technologies AB Company Information
13.2.2 Gyros Protein Technologies AB Psoriasis Biosimilar Product Portfolios and Specifications
13.2.3 Gyros Protein Technologies AB Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Gyros Protein Technologies AB Main Business Overview
13.2.5 Gyros Protein Technologies AB Latest Developments
13.3 Pfizer Inc.
13.3.1 Pfizer Inc. Company Information
13.3.2 Pfizer Inc. Psoriasis Biosimilar Product Portfolios and Specifications
13.3.3 Pfizer Inc. Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Pfizer Inc. Main Business Overview
13.3.5 Pfizer Inc. Latest Developments
13.4 Novartis International AG
13.4.1 Novartis International AG Company Information
13.4.2 Novartis International AG Psoriasis Biosimilar Product Portfolios and Specifications
13.4.3 Novartis International AG Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Novartis International AG Main Business Overview
13.4.5 Novartis International AG Latest Developments
13.5 Amgen Inc
13.5.1 Amgen Inc Company Information
13.5.2 Amgen Inc Psoriasis Biosimilar Product Portfolios and Specifications
13.5.3 Amgen Inc Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Amgen Inc Main Business Overview
13.5.5 Amgen Inc Latest Developments
13.6 Samsung Bioepis Co., Ltd.
13.6.1 Samsung Bioepis Co., Ltd. Company Information
13.6.2 Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Product Portfolios and Specifications
13.6.3 Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Samsung Bioepis Co., Ltd. Main Business Overview
13.6.5 Samsung Bioepis Co., Ltd. Latest Developments
13.7 Coherus BioSciences
13.7.1 Coherus BioSciences Company Information
13.7.2 Coherus BioSciences Psoriasis Biosimilar Product Portfolios and Specifications
13.7.3 Coherus BioSciences Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Coherus BioSciences Main Business Overview
13.7.5 Coherus BioSciences Latest Developments
13.8 Hoffmann-La Roche Ltd
13.8.1 Hoffmann-La Roche Ltd Company Information
13.8.2 Hoffmann-La Roche Ltd Psoriasis Biosimilar Product Portfolios and Specifications
13.8.3 Hoffmann-La Roche Ltd Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Hoffmann-La Roche Ltd Main Business Overview
13.8.5 Hoffmann-La Roche Ltd Latest Developments
13.9 Celltrion
13.9.1 Celltrion Company Information
13.9.2 Celltrion Psoriasis Biosimilar Product Portfolios and Specifications
13.9.3 Celltrion Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Celltrion Main Business Overview
13.9.5 Celltrion Latest Developments
13.10 Samsung Bioepis
13.10.1 Samsung Bioepis Company Information
13.10.2 Samsung Bioepis Psoriasis Biosimilar Product Portfolios and Specifications
13.10.3 Samsung Bioepis Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Samsung Bioepis Main Business Overview
13.10.5 Samsung Bioepis Latest Developments
13.11 Sandoz
13.11.1 Sandoz Company Information
13.11.2 Sandoz Psoriasis Biosimilar Product Portfolios and Specifications
13.11.3 Sandoz Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Sandoz Main Business Overview
13.11.5 Sandoz Latest Developments
13.12 Fresenius Kabi
13.12.1 Fresenius Kabi Company Information
13.12.2 Fresenius Kabi Psoriasis Biosimilar Product Portfolios and Specifications
13.12.3 Fresenius Kabi Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Fresenius Kabi Main Business Overview
13.12.5 Fresenius Kabi Latest Developments
13.13 Viatris
13.13.1 Viatris Company Information
13.13.2 Viatris Psoriasis Biosimilar Product Portfolios and Specifications
13.13.3 Viatris Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Viatris Main Business Overview
13.13.5 Viatris Latest Developments
13.14 Reddy's Laboratories
13.14.1 Reddy's Laboratories Company Information
13.14.2 Reddy's Laboratories Psoriasis Biosimilar Product Portfolios and Specifications
13.14.3 Reddy's Laboratories Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Reddy's Laboratories Main Business Overview
13.14.5 Reddy's Laboratories Latest Developments
13.15 GenScript
13.15.1 GenScript Company Information
13.15.2 GenScript Psoriasis Biosimilar Product Portfolios and Specifications
13.15.3 GenScript Psoriasis Biosimilar Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 GenScript Main Business Overview
13.15.5 GenScript Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Psoriasis Biosimilar Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Psoriasis Biosimilar Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
Table 4. Major Players of Other Biosimilars
Table 5. Global Psoriasis Biosimilar Sales by Type (2021-2026) & (K Units)
Table 6. Global Psoriasis Biosimilar Sales Market Share by Type (2021-2026)
Table 7. Global Psoriasis Biosimilar Revenue by Type (2021-2026) & ($ million)
Table 8. Global Psoriasis Biosimilar Revenue Market Share by Type (2021-2026)
Table 9. Global Psoriasis Biosimilar Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Psoriasis Biosimilar Sale by Application (2021-2026) & (K Units)
Table 11. Global Psoriasis Biosimilar Sale Market Share by Application (2021-2026)
Table 12. Global Psoriasis Biosimilar Revenue by Application (2021-2026) & ($ million)
Table 13. Global Psoriasis Biosimilar Revenue Market Share by Application (2021-2026)
Table 14. Global Psoriasis Biosimilar Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Psoriasis Biosimilar Sales by Company (2021-2026) & (K Units)
Table 16. Global Psoriasis Biosimilar Sales Market Share by Company (2021-2026)
Table 17. Global Psoriasis Biosimilar Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Psoriasis Biosimilar Revenue Market Share by Company (2021-2026)
Table 19. Global Psoriasis Biosimilar Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Psoriasis Biosimilar Producing Area Distribution and Sales Area
Table 21. Players Psoriasis Biosimilar Products Offered
Table 22. Psoriasis Biosimilar Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Psoriasis Biosimilar Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Psoriasis Biosimilar Sales Market Share Geographic Region (2021-2026)
Table 27. Global Psoriasis Biosimilar Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Psoriasis Biosimilar Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Psoriasis Biosimilar Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Psoriasis Biosimilar Sales Market Share by Country/Region (2021-2026)
Table 31. Global Psoriasis Biosimilar Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Psoriasis Biosimilar Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Psoriasis Biosimilar Sales by Country (2021-2026) & (K Units)
Table 34. Americas Psoriasis Biosimilar Sales Market Share by Country (2021-2026)
Table 35. Americas Psoriasis Biosimilar Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Psoriasis Biosimilar Sales by Type (2021-2026) & (K Units)
Table 37. Americas Psoriasis Biosimilar Sales by Application (2021-2026) & (K Units)
Table 38. APAC Psoriasis Biosimilar Sales by Region (2021-2026) & (K Units)
Table 39. APAC Psoriasis Biosimilar Sales Market Share by Region (2021-2026)
Table 40. APAC Psoriasis Biosimilar Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Psoriasis Biosimilar Sales by Type (2021-2026) & (K Units)
Table 42. APAC Psoriasis Biosimilar Sales by Application (2021-2026) & (K Units)
Table 43. Europe Psoriasis Biosimilar Sales by Country (2021-2026) & (K Units)
Table 44. Europe Psoriasis Biosimilar Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Psoriasis Biosimilar Sales by Type (2021-2026) & (K Units)
Table 46. Europe Psoriasis Biosimilar Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Psoriasis Biosimilar Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Psoriasis Biosimilar Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Psoriasis Biosimilar Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Psoriasis Biosimilar Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Psoriasis Biosimilar
Table 52. Key Market Challenges & Risks of Psoriasis Biosimilar
Table 53. Key Industry Trends of Psoriasis Biosimilar
Table 54. Psoriasis Biosimilar Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Psoriasis Biosimilar Distributors List
Table 57. Psoriasis Biosimilar Customer List
Table 58. Global Psoriasis Biosimilar Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Psoriasis Biosimilar Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Psoriasis Biosimilar Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Psoriasis Biosimilar Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Psoriasis Biosimilar Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Psoriasis Biosimilar Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Psoriasis Biosimilar Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Psoriasis Biosimilar Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Psoriasis Biosimilar Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Psoriasis Biosimilar Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Psoriasis Biosimilar Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Psoriasis Biosimilar Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Psoriasis Biosimilar Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Psoriasis Biosimilar Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Merck KGaA Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 73. Merck KGaA Psoriasis Biosimilar Product Portfolios and Specifications
Table 74. Merck KGaA Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Merck KGaA Main Business
Table 76. Merck KGaA Latest Developments
Table 77. Gyros Protein Technologies AB Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 78. Gyros Protein Technologies AB Psoriasis Biosimilar Product Portfolios and Specifications
Table 79. Gyros Protein Technologies AB Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Gyros Protein Technologies AB Main Business
Table 81. Gyros Protein Technologies AB Latest Developments
Table 82. Pfizer Inc. Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 83. Pfizer Inc. Psoriasis Biosimilar Product Portfolios and Specifications
Table 84. Pfizer Inc. Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Pfizer Inc. Main Business
Table 86. Pfizer Inc. Latest Developments
Table 87. Novartis International AG Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 88. Novartis International AG Psoriasis Biosimilar Product Portfolios and Specifications
Table 89. Novartis International AG Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Novartis International AG Main Business
Table 91. Novartis International AG Latest Developments
Table 92. Amgen Inc Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 93. Amgen Inc Psoriasis Biosimilar Product Portfolios and Specifications
Table 94. Amgen Inc Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Amgen Inc Main Business
Table 96. Amgen Inc Latest Developments
Table 97. Samsung Bioepis Co., Ltd. Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 98. Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Product Portfolios and Specifications
Table 99. Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Samsung Bioepis Co., Ltd. Main Business
Table 101. Samsung Bioepis Co., Ltd. Latest Developments
Table 102. Coherus BioSciences Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 103. Coherus BioSciences Psoriasis Biosimilar Product Portfolios and Specifications
Table 104. Coherus BioSciences Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Coherus BioSciences Main Business
Table 106. Coherus BioSciences Latest Developments
Table 107. Hoffmann-La Roche Ltd Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 108. Hoffmann-La Roche Ltd Psoriasis Biosimilar Product Portfolios and Specifications
Table 109. Hoffmann-La Roche Ltd Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Hoffmann-La Roche Ltd Main Business
Table 111. Hoffmann-La Roche Ltd Latest Developments
Table 112. Celltrion Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 113. Celltrion Psoriasis Biosimilar Product Portfolios and Specifications
Table 114. Celltrion Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Celltrion Main Business
Table 116. Celltrion Latest Developments
Table 117. Samsung Bioepis Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 118. Samsung Bioepis Psoriasis Biosimilar Product Portfolios and Specifications
Table 119. Samsung Bioepis Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Samsung Bioepis Main Business
Table 121. Samsung Bioepis Latest Developments
Table 122. Sandoz Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 123. Sandoz Psoriasis Biosimilar Product Portfolios and Specifications
Table 124. Sandoz Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Sandoz Main Business
Table 126. Sandoz Latest Developments
Table 127. Fresenius Kabi Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 128. Fresenius Kabi Psoriasis Biosimilar Product Portfolios and Specifications
Table 129. Fresenius Kabi Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Fresenius Kabi Main Business
Table 131. Fresenius Kabi Latest Developments
Table 132. Viatris Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 133. Viatris Psoriasis Biosimilar Product Portfolios and Specifications
Table 134. Viatris Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. Viatris Main Business
Table 136. Viatris Latest Developments
Table 137. Reddy's Laboratories Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 138. Reddy's Laboratories Psoriasis Biosimilar Product Portfolios and Specifications
Table 139. Reddy's Laboratories Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 140. Reddy's Laboratories Main Business
Table 141. Reddy's Laboratories Latest Developments
Table 142. GenScript Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 143. GenScript Psoriasis Biosimilar Product Portfolios and Specifications
Table 144. GenScript Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 145. GenScript Main Business
Table 146. GenScript Latest Developments
Table 1. Psoriasis Biosimilar Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Psoriasis Biosimilar Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
Table 4. Major Players of Other Biosimilars
Table 5. Global Psoriasis Biosimilar Sales by Type (2021-2026) & (K Units)
Table 6. Global Psoriasis Biosimilar Sales Market Share by Type (2021-2026)
Table 7. Global Psoriasis Biosimilar Revenue by Type (2021-2026) & ($ million)
Table 8. Global Psoriasis Biosimilar Revenue Market Share by Type (2021-2026)
Table 9. Global Psoriasis Biosimilar Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Psoriasis Biosimilar Sale by Application (2021-2026) & (K Units)
Table 11. Global Psoriasis Biosimilar Sale Market Share by Application (2021-2026)
Table 12. Global Psoriasis Biosimilar Revenue by Application (2021-2026) & ($ million)
Table 13. Global Psoriasis Biosimilar Revenue Market Share by Application (2021-2026)
Table 14. Global Psoriasis Biosimilar Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Psoriasis Biosimilar Sales by Company (2021-2026) & (K Units)
Table 16. Global Psoriasis Biosimilar Sales Market Share by Company (2021-2026)
Table 17. Global Psoriasis Biosimilar Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Psoriasis Biosimilar Revenue Market Share by Company (2021-2026)
Table 19. Global Psoriasis Biosimilar Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Psoriasis Biosimilar Producing Area Distribution and Sales Area
Table 21. Players Psoriasis Biosimilar Products Offered
Table 22. Psoriasis Biosimilar Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Psoriasis Biosimilar Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Psoriasis Biosimilar Sales Market Share Geographic Region (2021-2026)
Table 27. Global Psoriasis Biosimilar Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Psoriasis Biosimilar Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Psoriasis Biosimilar Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Psoriasis Biosimilar Sales Market Share by Country/Region (2021-2026)
Table 31. Global Psoriasis Biosimilar Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Psoriasis Biosimilar Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Psoriasis Biosimilar Sales by Country (2021-2026) & (K Units)
Table 34. Americas Psoriasis Biosimilar Sales Market Share by Country (2021-2026)
Table 35. Americas Psoriasis Biosimilar Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Psoriasis Biosimilar Sales by Type (2021-2026) & (K Units)
Table 37. Americas Psoriasis Biosimilar Sales by Application (2021-2026) & (K Units)
Table 38. APAC Psoriasis Biosimilar Sales by Region (2021-2026) & (K Units)
Table 39. APAC Psoriasis Biosimilar Sales Market Share by Region (2021-2026)
Table 40. APAC Psoriasis Biosimilar Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Psoriasis Biosimilar Sales by Type (2021-2026) & (K Units)
Table 42. APAC Psoriasis Biosimilar Sales by Application (2021-2026) & (K Units)
Table 43. Europe Psoriasis Biosimilar Sales by Country (2021-2026) & (K Units)
Table 44. Europe Psoriasis Biosimilar Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Psoriasis Biosimilar Sales by Type (2021-2026) & (K Units)
Table 46. Europe Psoriasis Biosimilar Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Psoriasis Biosimilar Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Psoriasis Biosimilar Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Psoriasis Biosimilar Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Psoriasis Biosimilar Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Psoriasis Biosimilar
Table 52. Key Market Challenges & Risks of Psoriasis Biosimilar
Table 53. Key Industry Trends of Psoriasis Biosimilar
Table 54. Psoriasis Biosimilar Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Psoriasis Biosimilar Distributors List
Table 57. Psoriasis Biosimilar Customer List
Table 58. Global Psoriasis Biosimilar Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Psoriasis Biosimilar Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Psoriasis Biosimilar Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Psoriasis Biosimilar Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Psoriasis Biosimilar Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Psoriasis Biosimilar Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Psoriasis Biosimilar Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Psoriasis Biosimilar Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Psoriasis Biosimilar Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Psoriasis Biosimilar Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Psoriasis Biosimilar Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Psoriasis Biosimilar Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Psoriasis Biosimilar Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Psoriasis Biosimilar Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Merck KGaA Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 73. Merck KGaA Psoriasis Biosimilar Product Portfolios and Specifications
Table 74. Merck KGaA Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Merck KGaA Main Business
Table 76. Merck KGaA Latest Developments
Table 77. Gyros Protein Technologies AB Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 78. Gyros Protein Technologies AB Psoriasis Biosimilar Product Portfolios and Specifications
Table 79. Gyros Protein Technologies AB Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Gyros Protein Technologies AB Main Business
Table 81. Gyros Protein Technologies AB Latest Developments
Table 82. Pfizer Inc. Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 83. Pfizer Inc. Psoriasis Biosimilar Product Portfolios and Specifications
Table 84. Pfizer Inc. Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Pfizer Inc. Main Business
Table 86. Pfizer Inc. Latest Developments
Table 87. Novartis International AG Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 88. Novartis International AG Psoriasis Biosimilar Product Portfolios and Specifications
Table 89. Novartis International AG Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Novartis International AG Main Business
Table 91. Novartis International AG Latest Developments
Table 92. Amgen Inc Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 93. Amgen Inc Psoriasis Biosimilar Product Portfolios and Specifications
Table 94. Amgen Inc Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Amgen Inc Main Business
Table 96. Amgen Inc Latest Developments
Table 97. Samsung Bioepis Co., Ltd. Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 98. Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Product Portfolios and Specifications
Table 99. Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Samsung Bioepis Co., Ltd. Main Business
Table 101. Samsung Bioepis Co., Ltd. Latest Developments
Table 102. Coherus BioSciences Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 103. Coherus BioSciences Psoriasis Biosimilar Product Portfolios and Specifications
Table 104. Coherus BioSciences Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Coherus BioSciences Main Business
Table 106. Coherus BioSciences Latest Developments
Table 107. Hoffmann-La Roche Ltd Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 108. Hoffmann-La Roche Ltd Psoriasis Biosimilar Product Portfolios and Specifications
Table 109. Hoffmann-La Roche Ltd Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Hoffmann-La Roche Ltd Main Business
Table 111. Hoffmann-La Roche Ltd Latest Developments
Table 112. Celltrion Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 113. Celltrion Psoriasis Biosimilar Product Portfolios and Specifications
Table 114. Celltrion Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Celltrion Main Business
Table 116. Celltrion Latest Developments
Table 117. Samsung Bioepis Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 118. Samsung Bioepis Psoriasis Biosimilar Product Portfolios and Specifications
Table 119. Samsung Bioepis Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Samsung Bioepis Main Business
Table 121. Samsung Bioepis Latest Developments
Table 122. Sandoz Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 123. Sandoz Psoriasis Biosimilar Product Portfolios and Specifications
Table 124. Sandoz Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Sandoz Main Business
Table 126. Sandoz Latest Developments
Table 127. Fresenius Kabi Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 128. Fresenius Kabi Psoriasis Biosimilar Product Portfolios and Specifications
Table 129. Fresenius Kabi Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Fresenius Kabi Main Business
Table 131. Fresenius Kabi Latest Developments
Table 132. Viatris Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 133. Viatris Psoriasis Biosimilar Product Portfolios and Specifications
Table 134. Viatris Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. Viatris Main Business
Table 136. Viatris Latest Developments
Table 137. Reddy's Laboratories Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 138. Reddy's Laboratories Psoriasis Biosimilar Product Portfolios and Specifications
Table 139. Reddy's Laboratories Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 140. Reddy's Laboratories Main Business
Table 141. Reddy's Laboratories Latest Developments
Table 142. GenScript Basic Information, Psoriasis Biosimilar Manufacturing Base, Sales Area and Its Competitors
Table 143. GenScript Psoriasis Biosimilar Product Portfolios and Specifications
Table 144. GenScript Psoriasis Biosimilar Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 145. GenScript Main Business
Table 146. GenScript Latest Developments
LIST OF FIGURES
Figure 1. Picture of Psoriasis Biosimilar
Figure 2. Psoriasis Biosimilar Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Psoriasis Biosimilar Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Psoriasis Biosimilar Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Psoriasis Biosimilar Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Psoriasis Biosimilar Sales Market Share by Country/Region (2025)
Figure 10. Psoriasis Biosimilar Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
Figure 12. Product Picture of Other Biosimilars
Figure 13. Global Psoriasis Biosimilar Sales Market Share by Type in 2026
Figure 14. Global Psoriasis Biosimilar Revenue Market Share by Type (2021-2026)
Figure 15. Psoriasis Biosimilar Consumed in Plaque Psoriasis
Figure 16. Global Psoriasis Biosimilar Market: Plaque Psoriasis (2021-2026) & (K Units)
Figure 17. Psoriasis Biosimilar Consumed in Psoriatic Arthritis
Figure 18. Global Psoriasis Biosimilar Market: Psoriatic Arthritis (2021-2026) & (K Units)
Figure 19. Psoriasis Biosimilar Consumed in Other
Figure 20. Global Psoriasis Biosimilar Market: Other (2021-2026) & (K Units)
Figure 21. Global Psoriasis Biosimilar Sale Market Share by Application (2025)
Figure 22. Global Psoriasis Biosimilar Revenue Market Share by Application in 2026
Figure 23. Psoriasis Biosimilar Sales by Company in 2026 (K Units)
Figure 24. Global Psoriasis Biosimilar Sales Market Share by Company in 2026
Figure 25. Psoriasis Biosimilar Revenue by Company in 2026 ($ millions)
Figure 26. Global Psoriasis Biosimilar Revenue Market Share by Company in 2026
Figure 27. Global Psoriasis Biosimilar Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Psoriasis Biosimilar Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Psoriasis Biosimilar Sales 2021-2026 (K Units)
Figure 30. Americas Psoriasis Biosimilar Revenue 2021-2026 ($ millions)
Figure 31. APAC Psoriasis Biosimilar Sales 2021-2026 (K Units)
Figure 32. APAC Psoriasis Biosimilar Revenue 2021-2026 ($ millions)
Figure 33. Europe Psoriasis Biosimilar Sales 2021-2026 (K Units)
Figure 34. Europe Psoriasis Biosimilar Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Psoriasis Biosimilar Sales 2021-2026 (K Units)
Figure 36. Middle East & Africa Psoriasis Biosimilar Revenue 2021-2026 ($ millions)
Figure 37. Americas Psoriasis Biosimilar Sales Market Share by Country in 2026
Figure 38. Americas Psoriasis Biosimilar Revenue Market Share by Country (2021-2026)
Figure 39. Americas Psoriasis Biosimilar Sales Market Share by Type (2021-2026)
Figure 40. Americas Psoriasis Biosimilar Sales Market Share by Application (2021-2026)
Figure 41. United States Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Psoriasis Biosimilar Sales Market Share by Region in 2026
Figure 46. APAC Psoriasis Biosimilar Revenue Market Share by Region (2021-2026)
Figure 47. APAC Psoriasis Biosimilar Sales Market Share by Type (2021-2026)
Figure 48. APAC Psoriasis Biosimilar Sales Market Share by Application (2021-2026)
Figure 49. China Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 53. India Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Psoriasis Biosimilar Sales Market Share by Country in 2026
Figure 57. Europe Psoriasis Biosimilar Revenue Market Share by Country (2021-2026)
Figure 58. Europe Psoriasis Biosimilar Sales Market Share by Type (2021-2026)
Figure 59. Europe Psoriasis Biosimilar Sales Market Share by Application (2021-2026)
Figure 60. Germany Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 61. France Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Psoriasis Biosimilar Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Psoriasis Biosimilar Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Psoriasis Biosimilar Sales Market Share by Application (2021-2026)
Figure 68. Egypt Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Psoriasis Biosimilar in 2026
Figure 74. Manufacturing Process Analysis of Psoriasis Biosimilar
Figure 75. Industry Chain Structure of Psoriasis Biosimilar
Figure 76. Channels of Distribution
Figure 77. Global Psoriasis Biosimilar Sales Market Forecast by Region (2027-2032)
Figure 78. Global Psoriasis Biosimilar Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Psoriasis Biosimilar Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Psoriasis Biosimilar Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Psoriasis Biosimilar Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Psoriasis Biosimilar Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Psoriasis Biosimilar
Figure 2. Psoriasis Biosimilar Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Psoriasis Biosimilar Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Psoriasis Biosimilar Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Psoriasis Biosimilar Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Psoriasis Biosimilar Sales Market Share by Country/Region (2025)
Figure 10. Psoriasis Biosimilar Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
Figure 12. Product Picture of Other Biosimilars
Figure 13. Global Psoriasis Biosimilar Sales Market Share by Type in 2026
Figure 14. Global Psoriasis Biosimilar Revenue Market Share by Type (2021-2026)
Figure 15. Psoriasis Biosimilar Consumed in Plaque Psoriasis
Figure 16. Global Psoriasis Biosimilar Market: Plaque Psoriasis (2021-2026) & (K Units)
Figure 17. Psoriasis Biosimilar Consumed in Psoriatic Arthritis
Figure 18. Global Psoriasis Biosimilar Market: Psoriatic Arthritis (2021-2026) & (K Units)
Figure 19. Psoriasis Biosimilar Consumed in Other
Figure 20. Global Psoriasis Biosimilar Market: Other (2021-2026) & (K Units)
Figure 21. Global Psoriasis Biosimilar Sale Market Share by Application (2025)
Figure 22. Global Psoriasis Biosimilar Revenue Market Share by Application in 2026
Figure 23. Psoriasis Biosimilar Sales by Company in 2026 (K Units)
Figure 24. Global Psoriasis Biosimilar Sales Market Share by Company in 2026
Figure 25. Psoriasis Biosimilar Revenue by Company in 2026 ($ millions)
Figure 26. Global Psoriasis Biosimilar Revenue Market Share by Company in 2026
Figure 27. Global Psoriasis Biosimilar Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Psoriasis Biosimilar Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Psoriasis Biosimilar Sales 2021-2026 (K Units)
Figure 30. Americas Psoriasis Biosimilar Revenue 2021-2026 ($ millions)
Figure 31. APAC Psoriasis Biosimilar Sales 2021-2026 (K Units)
Figure 32. APAC Psoriasis Biosimilar Revenue 2021-2026 ($ millions)
Figure 33. Europe Psoriasis Biosimilar Sales 2021-2026 (K Units)
Figure 34. Europe Psoriasis Biosimilar Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Psoriasis Biosimilar Sales 2021-2026 (K Units)
Figure 36. Middle East & Africa Psoriasis Biosimilar Revenue 2021-2026 ($ millions)
Figure 37. Americas Psoriasis Biosimilar Sales Market Share by Country in 2026
Figure 38. Americas Psoriasis Biosimilar Revenue Market Share by Country (2021-2026)
Figure 39. Americas Psoriasis Biosimilar Sales Market Share by Type (2021-2026)
Figure 40. Americas Psoriasis Biosimilar Sales Market Share by Application (2021-2026)
Figure 41. United States Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Psoriasis Biosimilar Sales Market Share by Region in 2026
Figure 46. APAC Psoriasis Biosimilar Revenue Market Share by Region (2021-2026)
Figure 47. APAC Psoriasis Biosimilar Sales Market Share by Type (2021-2026)
Figure 48. APAC Psoriasis Biosimilar Sales Market Share by Application (2021-2026)
Figure 49. China Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 53. India Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Psoriasis Biosimilar Sales Market Share by Country in 2026
Figure 57. Europe Psoriasis Biosimilar Revenue Market Share by Country (2021-2026)
Figure 58. Europe Psoriasis Biosimilar Sales Market Share by Type (2021-2026)
Figure 59. Europe Psoriasis Biosimilar Sales Market Share by Application (2021-2026)
Figure 60. Germany Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 61. France Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Psoriasis Biosimilar Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Psoriasis Biosimilar Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Psoriasis Biosimilar Sales Market Share by Application (2021-2026)
Figure 68. Egypt Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Psoriasis Biosimilar Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Psoriasis Biosimilar in 2026
Figure 74. Manufacturing Process Analysis of Psoriasis Biosimilar
Figure 75. Industry Chain Structure of Psoriasis Biosimilar
Figure 76. Channels of Distribution
Figure 77. Global Psoriasis Biosimilar Sales Market Forecast by Region (2027-2032)
Figure 78. Global Psoriasis Biosimilar Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Psoriasis Biosimilar Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Psoriasis Biosimilar Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Psoriasis Biosimilar Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Psoriasis Biosimilar Revenue Market Share Forecast by Application (2027-2032)
